Ertapenem

Ertapenem
Clinical data
Trade names	Invanz
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Pregnancy; category	AU: B3; ;
Routes of; administration	Intramuscular, intravenous
ATC code	J01DH03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	90% (intramuscular)
Protein binding	Inversely proportional to concentration; 85 to 95%
Metabolism	Minor hydrolysis of beta-lactam ring, CYP not involved
Elimination half-life	4 hours
Excretion	Renal (80%) and fecal (10%)
Identifiers
	IUPAC name (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]; pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-; oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid;
CAS Number	153832-46-3 ;
PubChem CID	150610;
DrugBank	DB00303 ;
ChemSpider	132758 ;
UNII	G32F6EID2H;
KEGG	D04049 ;
ChEBI	CHEBI:404903 ;
ChEMBL	ChEMBL1359 ;
CompTox Dashboard (EPA)	DTXSID50165456 ;
Chemical and physical data
Formula	C22H25N3O7S
Molar mass	475.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)c1cc(ccc1)NC(=O)[C@H]4NC[C@@H](S\C3=C(\N2C(=O)[C@H]([C@H](O)C)[C@H]2[C@H]3C)C(=O)O)C4;
	InChI InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1 ; Key:JUZNIMUFDBIJCM-ANEDZVCMSA-N ;
	(what is this?) (verify)

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz.^[1]

References

^ Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (November 2011). "Carbapenems: past, present, and future". Antimicrob. Agents Chemother. 55 (11): 4943–60. doi:10.1128/AAC.00296-11. PMC 3195018. PMID 21859938.